Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Covid-19 Vaccine Maker Stocks Higher Amid Variant Concerns

11/26/2021 | 12:07pm EST

By Michael Dabaie

Shares of Covid-19 vaccine makers Moderna Inc., Pfizer Inc. and BioNTech SE were higher Friday after South Africa raised alarms about a fast-spreading new variant of the coronavirus.

Moderna shares rose 26% to $345.54 and Pfizer was up 5.5% to $53.67, while American depositary receipts of BioNTech, which collaborates with Pfizer on a vaccine, were 21% higher to $369.11.

Equity markets were broadly lower amid concerns over the variant, with the Dow Jones Industrial Average, Nasdaq and S&P 500 each down more than 2%.

"The scientific, political and economic focus on the Nu variant is well founded despite the limited data," Citi said in commentary on the new variant. "The next two weeks with be critical to determine whether Nu will displace delta in countries with high background rates such as U.K. and Germany."

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

11-26-21 1206ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -13.66% 169.23 Delayed Quote.-34.36%
MODERNA, INC. -8.85% 186.61 Delayed Quote.-26.53%
PFIZER, INC. -1.53% 54.11 Delayed Quote.-8.37%
All news about MODERNA, INC.
01/18US Stocks Slump as Treasury Yields Hit 2-Year High, Goldman Sachs Weighs on Financials
MT
01/18US Stocks Start Week Lower as Treasury Yields Hit 2-Year High, Goldman Sachs Weighs on ..
MT
01/18Morgan Stanley Adjusts Moderna Price Target to $315 From $313, Maintains Equal Weight R..
MT
01/18Equities Slump Midday After Treasury Yields Touch Two-Year High, Goldman's Earnings Mis..
MT
01/18MIDDAY REPORT : US Stocks Slump After Treasury Yields Touch Two-Year High; Goldman's Earni..
MT
01/18EU regulator finds mRNA COVID-19 shots safe during pregnancy
RE
01/18European Medicines Agency Says mRNA COVID-19 Vaccines Safe In Pregnancy
MT
01/18EU regulator says mRNA COVID-19 shots do not complicate pregnancies
RE
01/18MARKETSCREENER’S WORLD PRESS REVIEW : January 18, 2022
01/17China's Xi rejects 'Cold War mentality,' pushes cooperation
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 520 M - -
Net income 2021 11 079 M - -
Net cash 2021 9 774 M - -
P/E ratio 2021 7,07x
Yield 2021 -
Capitalization 75 661 M 75 661 M -
EV / Sales 2021 3,76x
EV / Sales 2022 2,60x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Last Close Price 186,61 $
Average target price 273,19 $
Spread / Average Target 46,4%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-26.53%83 008
LONZA GROUP AG-15.15%53 950
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684
CELLTRION, INC.-19.44%18 710